Fig. 6From: RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trialAssessments during treatment (cycles 2–6), at end of treatment and at follow-up (arms A and B), and administration of treatment. CT computed tomography, PK pharmacokinetics, PET positron emission tomographyBack to article page